HRP20031079A2 - One dose vaccination with mycoplasma hyopneumoniae - Google Patents
One dose vaccination with mycoplasma hyopneumoniae Download PDFInfo
- Publication number
- HRP20031079A2 HRP20031079A2 HR20031079A HRP20031079A HRP20031079A2 HR P20031079 A2 HRP20031079 A2 HR P20031079A2 HR 20031079 A HR20031079 A HR 20031079A HR P20031079 A HRP20031079 A HR P20031079A HR P20031079 A2 HRP20031079 A2 HR P20031079A2
- Authority
- HR
- Croatia
- Prior art keywords
- vaccine
- hyo
- proteins
- bacterium
- polypeptides
- Prior art date
Links
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 title claims description 17
- 238000002255 vaccination Methods 0.000 title claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 85
- 229960005486 vaccine Drugs 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 67
- 102000004169 proteins and genes Human genes 0.000 claims description 57
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 42
- 229920001184 polypeptide Polymers 0.000 claims description 41
- 230000002163 immunogen Effects 0.000 claims description 37
- 239000012634 fragment Substances 0.000 claims description 21
- 241000282898 Sus scrofa Species 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 12
- 241000282887 Suidae Species 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 229940031626 subunit vaccine Drugs 0.000 claims description 10
- 241000204031 Mycoplasma Species 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- 208000023504 respiratory system disease Diseases 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 241000725681 Swine influenza virus Species 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 230000001850 reproductive effect Effects 0.000 claims description 2
- 241000204003 Mycoplasmatales Species 0.000 claims 4
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 claims 2
- 208000017443 reproductive system disease Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 53
- 210000004072 lung Anatomy 0.000 description 29
- 230000003902 lesion Effects 0.000 description 23
- -1 above) Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000002054 inoculum Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 102100036698 Golgi reassembly-stacking protein 1 Human genes 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 230000036039 immunity Effects 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 150000003839 salts Chemical group 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 108010041986 DNA Vaccines Proteins 0.000 description 4
- 229940021995 DNA vaccine Drugs 0.000 description 4
- 238000011887 Necropsy Methods 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 238000011886 postmortem examination Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 150000001793 charged compounds Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 229940023146 nucleic acid vaccine Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- JDRAOGVAQOVDEB-KTKRTIGZSA-N (3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl) (z)-octadec-9-enoate Chemical compound OC1COC2C(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-KTKRTIGZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710170970 Leukotoxin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- NKVLDFAVEWLOCX-GUSKIFEASA-N [(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl] (4ar,5r,6as,6br,9s,10s,12ar)-10-[(2r,3r,4s, Chemical compound O([C@H]1[C@H](O)CO[C@H]([C@@H]1O)O[C@H]1[C@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1OC(=O)[C@]12CCC(C)(C)CC1C1=CCC3[C@@]([C@@]1(C[C@H]2O)C)(C)CCC1[C@]3(C)CC[C@@H]([C@@]1(C)C=O)O[C@@H]1O[C@@H]([C@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O)C(=O)NCCCCCCCCCCCC)[C@@H]1OC[C@](O)(CO)[C@H]1O NKVLDFAVEWLOCX-GUSKIFEASA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 101150111411 p46 gene Proteins 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000001973 thioglycolate broth Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/87—Mycoplasma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30263601P | 2001-07-02 | 2001-07-02 | |
PCT/IB2002/002121 WO2003003941A2 (en) | 2001-07-02 | 2002-06-07 | One dose vaccination with mycoplasma hyopneumoniae |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20031079A2 true HRP20031079A2 (en) | 2005-10-31 |
Family
ID=23168589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20031079A HRP20031079A2 (en) | 2001-07-02 | 2003-12-23 | One dose vaccination with mycoplasma hyopneumoniae |
Country Status (42)
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY129765A (en) * | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
WO2006056841A1 (en) * | 2004-11-24 | 2006-06-01 | Pharmacia & Upjohn Company Llc | Multiple-strain mycoplasma hyopneumoniae vaccines |
US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
RU2488407C2 (ru) | 2005-12-29 | 2013-07-27 | Берингер Ингельхайм Ветмедика, Инк. | Поливалентные иммуногенные композиции pcv2 и способы получения таких композиций |
WO2007094893A2 (en) | 2005-12-29 | 2007-08-23 | Boehringer Ingelheim Vetmedica, Inc. | Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs |
CN101448521A (zh) * | 2006-03-03 | 2009-06-03 | 梅瑞尔有限公司 | 猪肺炎支原体疫苗 |
EP2099927A4 (de) * | 2006-11-22 | 2010-05-05 | Boehringer Ingelheim Vetmed | Verfahren zur reduzierung von mit schweine-circovirus assoziierten krankheitsausbrüchen |
US20100129397A1 (en) * | 2006-12-11 | 2010-05-27 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
PL2094872T5 (pl) | 2006-12-15 | 2020-10-05 | Boehringer Ingelheim Animal Health USA Inc. | Leczenie świń seropozytywnych wobec przeciwciała anty-pcv2 antygenem pcv2 |
EP1941903A1 (de) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxe und Behandlung von PRDC |
EP1958644A1 (de) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Vorbeugung und Behandlung von subklinischer PCVD |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
DK2217271T3 (en) * | 2007-11-06 | 2016-06-06 | Zoetis Services Llc | Avirulent, live vaccine with adjuvant against Mycoplasma hyopneumoniae |
AU2008347235A1 (en) * | 2007-12-31 | 2009-07-16 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 ORF2 virus like particle with foreign amino acid insertion |
CN101236206B (zh) * | 2008-01-17 | 2014-10-15 | 中国兽医药品监察所 | 一种猪肺炎支原体重组抗原elisa检测试剂盒 |
CA2712006A1 (en) | 2008-01-23 | 2009-10-15 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions |
US8444989B1 (en) * | 2008-04-18 | 2013-05-21 | Boehringer Ingelheim Vetmedica Gmbh | One dose vaccination against mycoplasma infections of pigs |
WO2009156960A2 (en) * | 2008-06-27 | 2009-12-30 | Pfizer Inc. | Novel adjuvant compositions |
TWI583403B (zh) | 2009-06-04 | 2017-05-21 | 國立感染症研究所 | 黴漿菌感染症用疫苗 |
TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物 |
EP2550362B1 (de) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv-glycoproteine und rekombinante vektoren |
WO2011141443A1 (en) | 2010-05-11 | 2011-11-17 | Intervet International B.V. | Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies |
SG187201A1 (en) * | 2010-07-26 | 2013-02-28 | Qu Biolog Inc | Immunogenic anti-inflammatory compositions |
WO2012025612A1 (en) * | 2010-08-27 | 2012-03-01 | Intervet International B.V. | Potency test for vaccine formulations |
US8546149B2 (en) | 2010-08-27 | 2013-10-01 | Intervet Inc. | Potency test for vaccine formulations |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
UA115053C2 (uk) * | 2012-03-07 | 2017-09-11 | Сева Санте Анімаль | Композиція, що містить антиген і ліпополісахарид у формі масло-в-воді, та спосіб її використання (варіанти) |
UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
UA114503C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
AU2013370983B2 (en) | 2012-12-28 | 2019-09-26 | Boehringer Ingelheim Vetmedica Gmbh | Method of making a mycoplasma vaccine |
UA121097C2 (uk) * | 2012-12-28 | 2020-04-10 | Бьорінгер Інгельхайм Ветмедіка Гмбх | Імуногенна композиція, що містить антигени мікоплазм |
BR112015018444A2 (pt) * | 2013-02-05 | 2018-05-08 | Agricultural Technology Research Institute | composição para prevenir infecção de mycoplasma spp., e vetor de expressão |
CN104338125A (zh) * | 2013-07-29 | 2015-02-11 | 普莱柯生物工程股份有限公司 | 一种猪肺炎支原体抗原在预防和治疗猪呼吸道疾病综合征方面的应用 |
JP6586083B2 (ja) | 2013-09-19 | 2019-10-02 | ゾエティス・サービシーズ・エルエルシー | 油性アジュバント |
CN105658660A (zh) | 2013-10-02 | 2016-06-08 | 勃林格殷格翰动物保健公司 | Pcv2 orf2蛋白变体和由其组成的病毒样颗粒 |
ES2714000T3 (es) * | 2013-11-21 | 2019-05-24 | Agricultural Tech Res Inst | Composición para prevenir y curar una infección por micoplasma |
CN105012948B (zh) * | 2014-04-18 | 2019-07-30 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其应用 |
CN104248753B (zh) * | 2014-05-15 | 2017-07-28 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其应用 |
BR102014014727B1 (pt) * | 2014-06-16 | 2018-04-03 | Ouro Fino Saúde Animal Ltda | COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae |
US9814769B2 (en) | 2014-09-30 | 2017-11-14 | Qatar University | Vaccines against pathogenic Escherichia coli and methods of using the same |
KR20170097116A (ko) | 2015-01-16 | 2017-08-25 | 조에티스 서비시즈 엘엘씨 | 구제역 백신 |
KR20160099223A (ko) * | 2015-02-12 | 2016-08-22 | 강원대학교산학협력단 | 마이코플라스마 하이오뉴모니애 박테린 백신 및 이의 제조방법 |
WO2018030878A1 (ko) * | 2016-08-12 | 2018-02-15 | 주식회사 이노백 | 재조합 단백질을 포함하는 돼지 마이코플라즈마 감염 예방용 백신 조성물 |
RU2668799C1 (ru) * | 2017-09-08 | 2018-10-02 | Эгрикалчурал Текнолоджи Рисерч Инститьют | Субъединичная вакцина против mycoplasma spp. |
CN108101969A (zh) * | 2017-11-13 | 2018-06-01 | 南京大爻网络科技有限公司 | 一种与猪支原体肺炎相关的抗原及其应用 |
RU2695679C1 (ru) * | 2018-09-11 | 2019-07-25 | Эгрикалчурал Текнолоджи Рисерч Инститьют | Субъединичная вакцина против mycoplasma spp. |
RU2759427C2 (ru) * | 2019-07-08 | 2021-11-12 | Эгрикалчурал Текнолоджи Рисерч Инститьют | Субъединичная вакцина против mycoplasma spp |
CN117305192A (zh) * | 2023-12-01 | 2023-12-29 | 北京瑞阳瑞泰生物科技有限公司 | 一种猪肺炎支原体rt02株、疫苗组合物及其应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0283840A3 (de) * | 1987-03-26 | 1989-08-09 | Ml Technology Ventures, L.P. | Mycoplasma hyopneuminiae-Antigen und seine Vewendungen |
US5252328A (en) * | 1987-03-26 | 1993-10-12 | Martin Marietta Energy Systems, Inc. | Mycoplasma hyopneumoniae antigen and uses therefor |
DE3881993T2 (de) | 1987-09-18 | 1993-09-30 | Akzo Nv | Mycoplasma-Impfstoff. |
HUT65827A (en) | 1990-04-02 | 1994-07-28 | Synergen Inc | Polypeptides useful in animal treatment against mycoplasma infections |
WO1991018627A1 (en) | 1990-05-29 | 1991-12-12 | Smithkline Beecham Corporation | Swine pneumonia vaccine and method for the preparation thereof |
US6113916A (en) * | 1990-05-29 | 2000-09-05 | American Cyanamid Company | Method of enhancing cell mediated immune responses |
US5565205A (en) | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
EP0475185A1 (de) | 1990-08-27 | 1992-03-18 | Nippon Flour Mills Co., Ltd. | DNA's, die für ein Oberflächenantigen von Mychoplasma hyopneumoniae kodidieren, DNA Fragmente für Primer, rekombinante antigene Peptide und diagnostische Methode für Mycoplasma Pneumoniae vom Schwein unter Nutzung derselben |
US5338543A (en) * | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
DE69333588T2 (de) * | 1992-09-28 | 2005-08-04 | Wyeth Holdings Corp. | Verfahren zur verstärkung zellularer immunantworten |
US5530874A (en) | 1993-02-02 | 1996-06-25 | 3Com Corporation | Network adapter with an indication signal mask and an interrupt signal mask |
WO1995009870A1 (en) | 1993-10-07 | 1995-04-13 | Iowa State University Research Foundation, Inc. | Characterization of mycoplasma hyopneumoniae adhesins |
BR9507717A (pt) | 1994-05-10 | 1997-09-23 | American Home Prod | Vacina brsv viva modificada aperfeiçoada |
US5788962A (en) | 1995-01-17 | 1998-08-04 | The Curators Of The University Of Missouri | DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures |
AUPN178995A0 (en) * | 1995-03-16 | 1995-04-13 | University Of Melbourne, The | Antigen composition |
CZ94899A3 (cs) | 1996-09-30 | 1999-09-15 | Embrex, Inc. | Vakcinační přípravek použitelný při produkci aktivní imunity, použití a způsob jeho přípravy |
EP0846468B1 (de) | 1996-12-05 | 2004-06-09 | Akzo Nobel N.V. | Nicht-virulentes Mycoplasma synoviae und Impfstoffe desselben |
WO1999026664A1 (en) | 1997-11-26 | 1999-06-03 | Iowa State University Research Foundation, Inc. | Recombinant mycoplasma hyopneumoniae vaccine |
AU6128900A (en) * | 1999-09-29 | 2001-04-05 | Pfizer Products Inc. | Nucleic acids and proteins of the mycoplasma hyopneumoniae mph3 gene and uses thereof |
US6585981B1 (en) * | 2000-07-27 | 2003-07-01 | Regents Of The University Of Minnesota | Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae |
UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
-
2002
- 2002-06-07 JP JP2003509957A patent/JP2005515162A/ja active Pending
- 2002-06-07 DE DE60229666T patent/DE60229666D1/de not_active Expired - Lifetime
- 2002-06-07 WO PCT/IB2002/002121 patent/WO2003003941A2/en active Application Filing
- 2002-06-07 PT PT02735755T patent/PT1474067E/pt unknown
- 2002-06-07 EP EP08167761.9A patent/EP2027873B8/de not_active Expired - Lifetime
- 2002-06-07 CA CA2451626A patent/CA2451626C/en not_active Expired - Lifetime
- 2002-06-07 CN CN200810186079.6A patent/CN101524532B/zh not_active Expired - Lifetime
- 2002-06-07 IL IL15934902A patent/IL159349A0/xx unknown
- 2002-06-07 TN TNPCT/IB2002/002121A patent/TNSN03155A1/fr unknown
- 2002-06-07 EP EP14182639.6A patent/EP2842569B1/de not_active Revoked
- 2002-06-07 HU HU0400434A patent/HU230246B1/hu unknown
- 2002-06-07 ES ES14182639T patent/ES2729579T3/es not_active Expired - Lifetime
- 2002-06-07 KR KR10-2004-7000044A patent/KR20040030785A/ko not_active Application Discontinuation
- 2002-06-07 ES ES02735755.7T patent/ES2312580T5/es not_active Expired - Lifetime
- 2002-06-07 EP EP02735755.7A patent/EP1474067B2/de not_active Expired - Lifetime
- 2002-06-07 AT AT02735755T patent/ATE412426T2/de active
- 2002-06-07 ES ES08167761.9T patent/ES2550458T3/es not_active Expired - Lifetime
- 2002-06-07 DK DK02735755.7T patent/DK1474067T4/en active
- 2002-06-07 CN CN201210389058.0A patent/CN102872456B/zh not_active Expired - Lifetime
- 2002-06-07 NZ NZ530106A patent/NZ530106A/en not_active IP Right Cessation
- 2002-06-07 SK SK1579-2003A patent/SK288010B6/sk unknown
- 2002-06-07 PL PL373367A patent/PL209773B1/pl unknown
- 2002-06-07 DK DK14182639.6T patent/DK2842569T3/da active
- 2002-06-07 AP APAP/P/2003/002937A patent/AP2003002937A0/en unknown
- 2002-06-07 BR BR0210804-6A patent/BR0210804A/pt not_active Application Discontinuation
- 2002-06-07 PT PT14182639T patent/PT2842569T/pt unknown
- 2002-06-07 MX MXPA03011599A patent/MXPA03011599A/es active IP Right Grant
- 2002-06-07 YU YU102203A patent/YU102203A/sh unknown
- 2002-06-07 PT PT81677619T patent/PT2027873E/pt unknown
- 2002-06-07 CN CN028133447A patent/CN1551781B/zh not_active Expired - Lifetime
- 2002-06-07 AU AU2002309109A patent/AU2002309109B2/en not_active Expired
- 2002-06-07 CZ CZ2003-3466A patent/CZ305781B6/cs not_active IP Right Cessation
- 2002-06-07 DK DK08167761.9T patent/DK2027873T3/en active
- 2002-06-07 EA EA200301323A patent/EA009901B1/ru not_active IP Right Cessation
- 2002-06-07 OA OA1200300344A patent/OA12638A/en unknown
- 2002-06-19 US US10/174,701 patent/US6846477B2/en not_active Ceased
- 2002-06-26 TW TW091114057A patent/TWI329514B/zh not_active IP Right Cessation
- 2002-06-26 DO DO2002000431A patent/DOP2002000431A/es unknown
- 2002-07-01 UY UY27366A patent/UY27366A1/es not_active Application Discontinuation
- 2002-07-01 PE PE2002000593A patent/PE20030285A1/es not_active Application Discontinuation
- 2002-07-01 AR ARP020102479A patent/AR034678A1/es not_active Application Discontinuation
- 2002-07-02 PA PA20028549701A patent/PA8549701A1/es unknown
- 2002-07-02 GT GT200200138A patent/GT200200138A/es unknown
- 2002-07-06 UA UA20031213200A patent/UA78707C2/uk unknown
-
2003
- 2003-12-12 ZA ZA2003/09698A patent/ZA200309698B/en unknown
- 2003-12-15 IS IS7076A patent/IS7076A/is unknown
- 2003-12-22 NO NO20035762A patent/NO342654B1/no not_active IP Right Cessation
- 2003-12-23 HR HR20031079A patent/HRP20031079A2/hr not_active Application Discontinuation
- 2003-12-31 MA MA27468A patent/MA27047A1/fr unknown
-
2004
- 2004-01-26 BG BG108546A patent/BG66481B1/bg unknown
- 2004-08-12 US US10/917,130 patent/US20050013823A1/en not_active Abandoned
-
2005
- 2005-01-13 HK HK05100335.9A patent/HK1068250A1/xx not_active IP Right Cessation
-
2009
- 2009-01-16 CY CY20091100059T patent/CY1108749T1/el unknown
- 2009-12-18 HK HK09111932.9A patent/HK1134900A1/xx not_active IP Right Cessation
-
2012
- 2012-03-02 US US13/411,232 patent/USRE44399E1/en not_active Expired - Lifetime
-
2013
- 2013-06-26 HK HK13107527.2A patent/HK1180224A1/zh not_active IP Right Cessation
-
2015
- 2015-08-27 HK HK15108334.1A patent/HK1207584A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20031079A2 (en) | One dose vaccination with mycoplasma hyopneumoniae | |
AU2002309109A1 (en) | One dose vaccination with mycoplasma hyopneumoniae | |
US7056492B2 (en) | Mycoplasma hyopneumoniae vaccine and methods for reducing Mycoplasma bovis pneumonia in cattle | |
HRP20031078A2 (en) | Mycoplasma bovis vaccine and methods of reducing pneumonia in animals | |
HRP20050660A2 (en) | Canine vaccines against bordetella bronchiseptica | |
WO2006056841A1 (en) | Multiple-strain mycoplasma hyopneumoniae vaccines | |
AU2002304305B2 (en) | Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle | |
AU2002304305A1 (en) | Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20080529 Year of fee payment: 7 |
|
ODBI | Application refused |